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Background-—Prior studies suggest that circulating fatty acids may inﬂuence the risk of atrial ﬁbrillation (AF), but little is known
about the associations of circulating saturated fatty acids with risk of AF.
Methods and Results-—The study population included 2899 participants from the Cardiovascular Health Study, a community-
based longitudinal cohort of adults aged 65 years or older in the United States who were free of prevalent coronary heart disease
and AF in 1992. Cox regression was used to assess the association of all the long-chain saturated fatty acids—palmitic acid (16:0),
stearic acid (18:0), arachidic acid (20:0), behenic acid (22:0), and lignoceric acid (24:0)—with incident AF. During a median of
11.2 years of follow-up, 707 cases of incident AF occurred. After adjustment for other AF risk factors, higher levels of circulating
16:0 were associated with a higher risk of AF (hazard ratio comparing highest and lowest quartiles: 1.48; 95% CI: 1.18, 1.86). In
contrast, higher levels of circulating 18:0, 20:0, 22:0, and 24:0 were each associated with a lower risk of AF. The hazard ratios
(95% CI) for AF in the top and bottom quartiles were 0.76 (95% CI: 0.61, 0.95) for 18:0; 0.78 (95% CI: 0.63, 0.97) for 20:0; 0.62
(95% CI: 0.50, 0.78) for 22:0; and 0.68 (95% CI: 0.55, 0.85) for 24:0.
Conclusions-—Results from this prospective cohort study of older adults demonstrate divergent associations of circulating
16:0 versus longer-chain saturated fatty acids with incident AF, highlighting the need to investigate both determinants of these
levels and potential pathways of the observed differential risk. (J Am Heart Assoc. 2014;3:e000889 doi: 10.1161/JAHA.114.
000889)
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A
trial ﬁbrillation (AF) is a common chronic arrhythmia
among older adults. In the United States, more than 3
million individuals have diagnosed AF, and this estimate is
expected to reach more than 7.5 million by 2050, as the
population ages.
1 Because AF is associated with a higher risk
of morbidity, including stroke, heart failure, cognitive decline,
and dementia,
2,3 identiﬁcation of risk factors associated with
AF is of considerable public health importance.
Prior studies suggest that circulating fatty acids may
inﬂuence the risk of AF. In the Cardiovascular Health Study
(CHS), plasma phospholipid long-chain n-3 fatty acids derived
from seafood, particularly eicosapentaenoic acid and docosa-
hexaenoic acid, were inversely associated with risk of AF.
4
Conversely, there was no evidence of an association of
circulating levels of plant-derived a-linolenic acid and AF.
5
Little is known about the associations of circulating saturated
fatty acids (SFAs) with AF. SFAs are derived from both
endogenous and exogenous sources, and for this reason,
circulating SFAs generally show low correlations with dietary
intake of SFAs. SFAs of different length differ in incorporation
into membrane lipid species, membrane properties, and
biological activity. In addition, SFAs also differ in their dietary
sources. The SFAs palmitic acid (16:0) and stearic acid (18:0)
are found in animal products, such as meat and hard cheeses,
and in tropical oils, whereas arachidic acid (20:0), behenic
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ORIGINAL RESEARCHacid (22:0), and lignoceric acid (24:0) are found in peanuts
and canola oil. SFA 16:0 is also the primary end product of
fatty acid synthesis,
6–8 and circulating levels of 16:0 are
inﬂuenced by carbohydrate and alcohol intake.
9–11
To date, some observational studies,
12–16 but not all,
11,17
suggest that individual SFAs may have differential effects of
risk on cardiovascular disease and its risk factors. A handful
of in vitro experiments with cardiac myocytes did not ﬁnd any
effect of 18:0 on calcium and sodium currents or membrane
electrical excitability,
18–20 and no published studies have
examined the effect of very long-chain SFAs 20:0, 22:0, and
24:0 on electrophysiology parameters. To elucidate how
levels of different circulating SFAs are associated with AF, we
examined the associations of plasma phospholipid 16:0, 18:0,
20:0, 22:0, and 24:0 with incident AF in the CHS, a
population-based longitudinal cohort of older adults.
Methods
Study Population
The CHS is a longitudinal study of cardiovascular disease
among noninstitutionalized adults aged 65 years or older
from 4 communities in the United States (Forsyth County,
North Carolina; Sacramento County, California; Washington
Country, Maryland; Allegheny County, Pennsylvania). Details
of the study design and sampling procedures have been
reported previously.
21 In total, 5201 participants enrolled in
the study in 1989–1990 and 687 participants (largely black)
enrolled in 1992–1993. Study participants were followed by
annual clinic visits with interim 6-month follow-up phone calls
until 1999–2000 and by phone contact every 6 months
thereafter. The institutional review board at each site
approved the study, and written informed consent was
obtained from participants at enrollment.
Plasma phospholipid fatty acids were measured in 3941
participants using stored blood samples from 1992 to 1993,
considered the baseline for the present analysis. We excluded
233 participants with prevalent AF and 809 participants with
prevalent coronary heart disease because a diagnosis of
coronary heart disease may have inﬂuenced diet and plasma
phospholipid fatty acid levels. The remaining 2899 persons
composed the study population for the current analysis.
Data Collection
At baseline and during follow-up, participants underwent
comprehensive annual clinic examinations that included a
standardized interview, physical examination, laboratory
assessment, and diagnostic tests. Information regarding past
medical conditions, smoking, alcohol consumption, and other
health behaviors were collected. Blood samples were collected
after a 12-hour overnight fast and stored at 70°C. To
measure usual dietary intake, reproducible and validated food
frequency questionnaires (FFQs) were administered in 1989
and 1996. The 1989 FFQ was a picture version of the National
Cancer Registry FFQ and included 99 food items.
22 In 1996,
the Willett 131-item semiquantitative FFQ was administered.
23
Because the blood samples used to measure plasma phos-
pholipid fatty acids for the present analysis were collected
during 1992–1993, we cumulatively updated responses to the
2 FFQs for participants who completed both the 1990 and the
1996 FFQs and did not develop coronary heart disease during
1989–1996 (n=1927). For participants who developed coro-
nary heart disease during 1989–1996, only the 1989–1990
dietary measure was used for analyses (n=202). We chose not
to update diet among participants who developed coronary
heart disease during follow-up because diagnosis may have
inﬂuenced diet and risk of AF. For participants who enrolled in
CHS during 1992–1993 (n=263), the 1995–1996 diet mea-
sure was used for analyses.
Assessment of Plasma Phospholipid SFAs
Plasma phospholipid fatty acids were measured at the Fred
Hutchinson Cancer Research Center (Seattle, Washington)
using stored blood samples from 1992 to 1993. Total lipids
were extracted from plasma using the methods of Folch
et al.
24 One-dimensional thin-layer chromatography was used
to separate phospholipids from neutral lipids. Phospholipids
fraction was directly transesteriﬁed using the method of
Lepage and Roy to prepare fatty acid methyl esters,
25 and
individual fatty acid methyl esters were separated using gas
chromatography (Agilent 5890 Gas Chromatograph ﬂame
ionization detector, Agilent Technologies; fused silica capillary
column SP-2560 [10090.25 mm, 0.2 lm], Supelco; initial
160°C for 16 minutes, ramp 3°C per minute to 240°C, hold
15 minutes).
26 All fatty acids were processed at the biomar-
ker laboratory of the Fred Hutchinson Cancer Research
Center. For this analysis, levels of each individual fatty acid
including 16:0, 18:0, 20:0, 22:0, and 24:0 are expressed as a
weight percentage of total phospholipid fatty acids analyzed.
Ascertainment of AF
Incident AF, including atrial ﬂutter, was identiﬁed from 12-lead
ECGs performed annually until 1999 or was based on hospital
discharge diagnoses (International Classiﬁcation of Diseases,
9th revision codes 427.3, 427.31, 427.32) through June 30,
2008. Review of medical records of a subsample of partic-
ipants in the CHS with a hospital discharge code for AF
indicates that the positive predictive value of AF identiﬁcation
through hospital diagnosis codes was 98.6%.
27 In addition,
among 819 CHS participants who underwent a 24-hour Holter
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Statistical Analyses
All statistical analyses were conducted using Stata version
10.0 (StataCorp). Cox proportional hazard models were used
to examine the associations of each plasma phospholipid SFA
with incident AF. Plasma phospholipid SFAs were assessed
categorically using indicator quartiles. We examined the
associations of individual SFAs with the hazard of developing
AF in live subjects, so deaths from any cause were treated the
same way as censoring due to loss to follow-up (1211
participants censored due to death). All participants were
followed until the end of follow-up (June 30, 2008), loss to
follow-up, date of death, or development of AF. We did not
run formal analyses to assess the competing risk of death
because our focus was solely on AF risk. The proportional
hazards assumption for each SFA was evaluated using
Schoenfeld’s residuals.
Two levels of adjustment were used to examine the
associations of each SFA of interest with incident AF. Minimal
adjustments included age and sex. The primary model
additionally included race (European American, African Amer-
ican, other), enrollment site (Forsyth County, North Carolina;
Sacramento County, California; Washington Country, Mary-
land; Allegheny County, Pennsylvania), education (no high
school, high school or vocational school, college), and body
mass index (kilograms per square meter), waist circumference
(centimeters), smoking (never, past, current), alcohol use
(drinks per week), physical activity (kilocalories per week),
diabetes (yes or no), history of heart failure (yes or no), history
of stroke (yes or no), treated hypertension (yes or no), and
plasma phospholipid long-chain n-3 fatty acids (percentage of
total fatty acids) at baseline. Because exposure misclassiﬁ-
cation may increase with increasing duration of follow-up and
ascertainment of AF may have been better in the earlier years
of follow-up (ie, AF ascertained by both ECG and hospital
discharge code through 1999), we performed sensitivity
analyses censoring at the midpoint of follow-up, 8 years after
the 1992–1993 blood draw. It is possible that the associa-
tions between SFAs and AF may differ by sex, age, or
hypertension status,
29,30 and we examined potential effect
modiﬁcation of each of these factors with each SFA (modeled
linearly) on risk of AF by evaluating the statistical signiﬁcance
of the multiplicative interaction term using Wald’s tests. We
also performed sensitivity analyses stratiﬁed by sex, age
(median, 74 years), and hypertension status (yes or no) as
well as cross-tabulation analyses stratiﬁed at the median of
each SFA of interest and age. Finally, because the SFAs of
interest were correlated, we performed exploratory models
that additionally adjusted for SFA 16:0 and for all other SFAs
(ie, 16:0, 18:0, 20:0, 22:0, and 24:0, as appropriate).
Missing covariates (<2% for all covariates, except alcohol
intake; missing 4.0%) were imputed by multiple imputations
using data on age, sex, smoking, education, race, body mass
index, physical activity, self-reported health status, and
diabetes at the time of the plasma phospholipid SFA measure.
Results
At baseline in 1992–1993, the median age was 74 years
(range: 65 to 98 years), and 63.6% of the sample was female.
Levels of SFA were between 0.16% and 33.1% of total plasma
phospholipid fatty acids (Table 1). The highest values
were observed for 16:0 (meanSD: 25.41.59), whereas
the lowest values were observed for 20:0 (meanSD:
0.500.08). Plasma phospholipid levels of 16:0, 18:0, 20:0,
22:0, and 24:0 were generally modestly intercorrelated,
except for higher correlations of 20:0 and 22:0 (r=0.63) and
22:0 and 24:0 (r=0.88). Notably, all intercorrelations were
positive except for those of 16:0, which inversely correlated
with the other SFAs.
Characteristics of the study participants according to
levels of plasma phospholipids 16:0 and 24:0 are shown in
Table 2. In these crude (unadjusted) analyses, participants
Table 1. Pearson Correlation Coefﬁcients for Plasma Phospholipid Saturated Fatty Acids
Percentage of Total Fatty Acids*
16:0 18:0 20:0 22:0 24:0
25.4 (1.59) 13.4 (1.10) 0.50 (0.08) 1.68 (0.32) 1.40 (0.29)
16:0 1.00
18:0 0.52 1.00
20:0 0.31 0.20 1.00
22:0 0.46 0.15 0.63 1.00
24:0 0.36 0.07 0.46 0.88 1.00
*Values are mean (SD).
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Hwith higher 16:0 were more likely to be male and white, were
more highly educated, consumed more alcohol per week, and
were more likely to have diabetes when compared with
participants with lower 16:0. Conversely, minimal differences
according to 16:0 levels were evident in other AF risk factors,
including age; smoking status; body mass index; aspirin or
lipid-lowering drug use; cystatin C; estimated glomular
ﬁltration rate; or prevalent treated hypertension, stroke, or
heart failure. Similar to 16:0, participants with higher
circulating 24:0 were more likely to be male and have
higher education when compared with participants
with lower circulating 24:0. In contrast to 16:0, participants
with higher 24:0 were younger, less likely to be white, had
slightly lower body mass index, and were less likely to have
estimated glomular ﬁltration rate <60 mL/min per 1.73 m
2.
Participants with higher levels of circulating 24:0 also had
slightly higher dietary intake of peanuts, total fat, and
polyunsaturated fat when compared with participants with
lower levels of circulating 24:0. There were no apparent
differences in alcohol intake; aspirin use; or histories of
diabetes, hypertension, or heart failure, according to quartile
of plasma phospholipid 24:0. Baseline characteristics of study
participants according to quartiles of plasma phospholipid
18:0, 20:0, and 22:0 are provided in Table 3.
Plasma Phospholipid SFAs and Incident AF
During 29 864 person-years of follow-up, 707 cases of
incident AF occurred. In both age- and sex-adjusted and
multivariable analyses, higher levels of circulating 16:0 were
associated with a higher risk of AF (Table 4). Risk estimates
across quartiles suggested a monotonic dose response, with
multivariate hazard ratios of 1.12 (95% CI: 0.89 to 1.40), 1.25
(95% CI: 0.99 to 1.56), and 1.48 (95% CI: 1.18 to 1.86) from
the second to fourth quartiles compared with the ﬁrst (P-
trend<0.0001). Conversely, higher circulating levels of 18:0,
20:0, and 24:0 were each associated with lower risk of AF.
Comparing each of the upper quartiles with the lowest
quartile of plasma phospholipid 18:0, the hazard ratios for AF
were 0.89 (95% CI: 0.72 to 1.09), 0.77 (95% CI: 0.62 to 0.95),
and 0.76 (95% CI: 0.61 to 0.95) (P-trend=0.01) (Table 4).
Results for 20:0, 22:0, and 24:0 appeared similar to or
stronger than those of 18:0 (Table 5). Restricting analyses to
the ﬁrst 8 years of follow-up did not materially alter results
(data not shown). There was no evidence of interaction of age,
sex, or hypertension status with each SFA on risk of AF, and
associations of SFAs with AF incidence were similar in
analyses stratiﬁed by sex, age, and hypertension status (data
not shown). Results of cross-tabulation analyses suggest no
major subgroup effects of age on the associations of each
SFA with AF (Tables 6 through 10). Exploratory models that
included all 5 SFAs resulted in attenuated hazard ratios that
were no longer signiﬁcant (data not shown). In exploratory
analyses, the associations of 22:0 and 24:0, but not that of
18:0 and 20:0, remained signiﬁcant with adjustment for 16:0
(data not shown).
Discussion
In this large, prospective, community-based cohort study of
older US adults, objective SFA biomarkers were associated
with incident AF. Speciﬁcally, plasma phospholipid 16:0 was
associated with signiﬁcantly higher risk, whereas 18:0, 20:0,
22:0, and 24:0 were each associated with signiﬁcantly lower
risk. These data support the hypothesis that the health effects
of circulating SFAs, or the metabolic determinants of their
circulating levels, may differ by chain length.
Individual SFAs have different dietary and metabolic
origins. Whereas 16:0 is the most abundant SFA in both diet
and circulation, its circulating levels are poorly correlated with
dietary intake.
31,32 This suggests that metabolic pathways are
the primary determinant of circulating levels. One key driver
of higher circulating 16:0 appears to be de novo lipogenesis,
an endogenous enzymatic pathway by which dietary carbo-
hydrates are converted into circulating fatty acids in the
presence of low-fat and high-carbohydrate diets.
6–8,33 Alcohol
intake may also drive the endogenous synthesis of 16:0.
9–11
Similar to 16:0, SFA 18:0 can be derived from animal
products, including beef and hard cheeses,
34 but it also can
be found in other food sources, such as shea butter, cocoa
butter, and chocolate.
35,36 SFA 18:0 may also be produced
endogenously from the elongation of 16:0.
37 Recent studies
have demonstrated the unique effects of 18:0 on plasma
lipids and lipoproteins; unlike other SFAs, including 16:0, that
are associated with hypercholesterolemia, 18:0 has no
effect on lipid metabolism.
31,38 Although the biological
mechanism underlying these differential effects is unknown,
this ﬁnding highlights potential, diverse physiological
effects and/or underlying metabolic pathways of individual
SFAs.
Very long-chain SFAs 20:0, 22:0, and 24:0 are derived from
dietary sources, such as peanuts and canola oil, and may also
be produced endogenously from the elongation of 18:0 to
20:0, 22:0, and 24:0.
37,39 Very long-chain SFAs exhibit
distinct functions when compared with other long-chain SFAs.
Very long-chain SFAs, for example, are known to inﬂuence
liver homeostasis, retinal function, and anti-inﬂammatory
functions.
40 Unfortunately, little is known about very long-
chain SFA, and more studies are needed to better understand
the pathways by which these SFAs may inﬂuence human
health and disease.
The biological mechanisms by which circulating SFAs may
inﬂuence risk of AF are largely unknown. Increasing experi-
mental evidence suggests that the long-chain SFA 16:0 may
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Hincrease apoptosis, whereas very long-chain SFAs (20:0, 22:0,
and 24:0) may decrease apoptosis.
41–44 Animal and human
studies suggest a role of apoptosis in the pathophysiology of
AF, including ﬁbrosis and the progressive remodeling leading
to AF,
45–50 suggesting a possible mechanism by which higher
levels of plasma phospholipid 16:0 may be associated with a
higher risk of AF, whereas 20:0, 22:0, and 24:0 may be
associated with a lower risk of AF. More research is needed to
better understand how circulating SFAs may inﬂuence risk
of AF.
Table 4. Hazard Ratio for Incident Atrial Fibrillation According to Plasma Phospholipid Long- Chain Saturated Fatty Acids
Quartile Q1 Q2 Q3 Q4 P-trend
16:0
Person-years 7925.3 7704.3 7181.9 7052.1
No. of cases 151 172 183 201
Hazard ratio (95% CI)
Age and sex adjusted 1.0 (ref) 1.12 (0.90 to 1.39) 1.24 (1.00 to 1.54) 1.47 (1.19 to 1.82) <0.0001
Multivariate model* 1.0 (ref) 1.12 (0.89 to 1.40) 1.25 (0.99 to 1.56) 1.48 (1.18 to 1.86) <0.0001
18:0
Person-years 6821.1 7382.6 7797.3 7862.6
No. of cases 196 188 160 163
Hazard ratio (95% CI)
Age and sex adjusted 1.0 (ref) 0.89 (0.73 to 1.09) 0.76 (0.62 to 0.94) 0.81 (0.65 to 1.00) 0.02
Multivariate model* 1.0 (ref) 0.89 (0.72 to 1.09) 0.77 (0.62 to 0.95) 0.76 (0.61 to 0.95) 0.01
*Adjusted for age, sex, race, clinic, education, smoking, alcohol use, body mass index, waist circumference, physical activity, treated hypertension, diabetes, history of stroke, history of
heart failure, and plasma phospholipid long-chain n-3 fatty acids.
Table 5. Hazard Ratio for Incident Atrial Fibrillation According to Plasma Phospholipid Very Long-Chain Saturated Fatty Acids
Quartile Q1 Q2 Q3 Q4 P-trend
20:0
Person-years 6696.2 7419.0 7791.0 7957.4
No. of cases 203 175 161 168
Hazard ratio (95% CI)
Age and sex adjusted 1.0 (ref) 0.75 (0.61 to 0.92) 0.68 (0.55 to 0.84) 0.71 (0.58 to 0.87) 0.001
Multivariate model* 1.0 (ref) 0.77 (0.63 to 0.95) 0.71 (0.57 to 0.87) 0.78 (0.63 to 0.97) 0.01
22:0
Person-years 6496.4 6995.9 8034.3 8337.0
No. of cases 205 172 174 156
Hazard ratio (95% CI)
Age and sex adjusted 1.0 (ref) 0.75 (0.61 to 0.92) 0.67 (0.55 to 0.82) 0.61 (0.49 to 0.75) <0.0001
Multivariate model* 1.0 (ref) 0.75 (0.61 to 0.92) 0.72 (0.58 to 0.89) 0.62 (0.50 to 0.78) <0.0001
24:0
Person-years 6445.8 7368.9 7600.1 8448.7
No. of cases 198 173 175 161
Hazard ratio (95% CI)
Age and sex adjusted 1.0 (ref) 0.75 (0.61 to 0.92) 0.71 (0.58 to 0.87) 0.60 (0.49 to 0.74) <0.0001
Multivariate model* 1.0 (ref) 0.82 (0.67 to 1.01) 0.77 (0.63 to 0.96) 0.68 (0.55 to 0.85) 0.001
*Adjusted for age, sex, race, clinic, education, smoking, alcohol use, body mass index, waist circumference, physical activity, treated hypertension, diabetes, history of stroke, history of
heart failure, and plasma phospholipid long-chain n-3 fatty acids.
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associations of circulating SFAs with incident AF, and results
of studies that have examined associations of circulating
SFAs with risk factors for AF (eg, hypertension, myocar-
dial infarction, heart failure) have shown inconsistent ﬁnd-
ings.
11–17 Two previous studies examined the relationship of
circulating 16:0 and 18:0 with cardiovascular events. Results
from a population-based retrospective case control study
indicated that higher levels of circulating 16:0, but not 18:0,
are associated with a higher risk of sudden cardiac arrest. In
that study, a 1-SD-higher level of circulating 16:0 was
associated with a 38% higher risk.
17 In contrast, a previous
analysis in CHS was not able to demonstrate an association of
16:0 and 18:0 with sudden cardiac arrest and showed little
evidence of a strong association of these fatty acids with
incident coronary heart disease. The study showed, however,
that higher levels of circulating 18:1n-7, a fatty acid derived
from the desaturation and elongation of 16:0, were associated
with a 7-fold higher risk of sudden cardiac arrest.
11
Our study has several strengths. CHS is a large, multicen-
ter, longitudinal study in older adults, a population with high
risk of AF. The prospective analysis and cohort design
reduced potential for both recall bias and selection bias. In
addition, individual SFAs were measured using an objective
biomarker. The use of multiple methods to identify AF
(hospital discharge records, ECGs) may lower the possibility
of misclassiﬁcation of AF. Detailed information on demo-
graphic and clinical factors was collected using standard
instruments, which increased our ability to adjust for
confounding. Finally, the community-based enrollment of the
cohort increased generalizability.
This analysis also has potential limitations. Plasma phos-
pholipid fatty acids were assessed only at a single time point
(1992–1993), and we were unable to account for potential
changes in circulating levels of SFAs due to changes in diet or
metabolism over the 16-year follow-up. Although the FFQs
provided a measure of average daily energy and nutrient
intake, many of the foods high in SFAs (eg, canola oil, tropical
oils, hard cheese, and nuts) were not included on the FFQs,
and we were unable to examine the relationship of circulating
SFAs and dietary SFAs. Annual ECGs were performed only
through 1999, and it is possible that ascertainment of AF was
better during 1992–1999 than during 2000–2008; however,
restricting analyses to the ﬁrst 8 years of follow-up did not
Table 7. Hazard Ratios for Incident Atrial Fibrillation
According to Plasma Phospholipid 18:0 and Age*
Age <74 y Age ≥74 y
Plasma phospholipid
18:0 <13.4% total
fatty acids
1.00 0.89 (0.67 to 1.19)
Plasma phospholipid
18:0 ≥13.4% total
fatty acids
0.76 (0.60 to 0.95) 0.78 (0.58 to 1.09)
Plasma phospholipid 18:0 and age are both stratiﬁed at the median.
*Adjusted for age, sex, race, clinic, education, smoking, alcohol use, body mass index,
waist circumference, physical activity, treated hypertension, diabetes, history of stroke,
history of heart failure, and plasma phospholipid long-chain n-3 fatty acids.
Table 8. Hazard Ratios for Incident Atrial Fibrillation
According to Plasma Phospholipid 20:0 and Age*
Age <74 y Age ≥74 y
Plasma phospholipid
20:0 <0.50% total
fatty acids
1.00 0.88 (0.67 to 1.16)
Plasma phospholipid
20:0 ≥0.50% total
fatty acids
0.75 (0.60 to 0.94) 0.80 (0.60 to 1.06)
Plasma phospholipid 20:0 and age are both stratiﬁed at the median.
*Adjusted for age, sex, race, clinic, education, smoking, alcohol use, body mass index,
waist circumference, physical activity, treated hypertension, diabetes, history of stroke,
history of heart failure, and plasma phospholipid long-chain n-3 fatty acids.
Table 9. Hazard Ratios for Incident Atrial Fibrillation
According to Plasma Phospholipid 22:0 and Age*
Age <74 y Age ≥74 y
Plasma phospholipid
22:0 <1.67% total
fatty acids
1.00 0.90 (0.68 to 1.19)
Plasma phospholipid
22:0 ≥1.67% total
fatty acids
0.74 (0.59 to 0.93) 0.74 (0.56 to 1.00)
Plasma phospholipid 22:0 and age are both stratiﬁed at the median.
*Adjusted for age, sex, race, clinic, education, smoking, alcohol use, body mass index,
waist circumference, physical activity, treated hypertension, diabetes, history of stroke,
history of heart failure, and plasma phospholipid long-chain n-3 fatty acids.
Table 6. Hazard Ratios for Incident Atrial Fibrillation
According to Plasma Phospholipid 16:0 and Age*
Age <74 y Age ≥74 y
Plasma phospholipid
16:0 <25.3% total
fatty acids
1.00 0.97 (0.72 to 1.30)
Plasma phospholipid
16:0 ≥25.3% total
fatty acids
1.27 (1.01 to 1.59) 1.20 (0.90 to 1.61)
Plasma phospholipid 18:0 and age are both stratiﬁed at the median.
*Adjusted for age, sex, race, clinic, education, smoking, alcohol use, body mass index,
waist circumference, physical activity, treated hypertension, diabetes, history of stroke,
history of heart failure, and plasma phospholipid long-chain n-3 fatty acids.
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hospital discharge diagnoses to identify incident AF, newly
recognized paroxysmal AF that was managed only in the
outpatient setting may have been missed. Conversely, such
patients often eventually receive a hospital diagnosis of AF, so
some of these AF diagnoses were likely simply delayed rather
than missed entirely. Although we adjusted for several factors
associated with SFA levels and AF risk, residual confounding
by unknown or poorly measured factors is possible. Our
analyses assessed the associations of multiple SFAs on risk of
AF, increasing the possibility that our ﬁndings may be due to
chance alone. We decided not to adjust for multiple compar-
isons in the analyses because the circulating SFAs were
moderately to highly correlated. Moreover, the high correla-
tion of some of the circulating SFAs, particularly 22:0 and
24:0, limited our ability to isolate the effects of individual fatty
acids on risk of AF, and interpretation of analyses that
mutually adjusted for all SFAs is challenging. Finally, our
cohort comprised participants aged 65 years or older, and
results may not be generalizable to younger populations, in
which AF is far less frequent.
In conclusion, the results of this analysis suggest that
among older adults, higher levels of circulating 16:0 are
associated with a higher risk of AF, whereas higher levels of
circulating 18:0, 20:0, 22:0, and 24:0 are associated with
lower risk. This study adds to the growing body of evidence
suggesting potential differences in the health effects and/or
underlying metabolic determinants of different types of
circulating SFAs. These novel ﬁndings highlight the need for
further observational and mechanistic investigation to
better understand how circulating SFAs may inﬂuence risk
of AF.
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